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Background: YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of
the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma
after appropriate treatment and to evaluate the correlation of YKL-40 levels with lung function and asthma control
test (ACT) results.
Methods: A total of 103 asthmatic patients (mean age 33.1 ± 0.9 years) with diagnosed asthma were enrolled in
our study. All patients underwent a detailed clinical examination and completed the ACT questionnaire, serum YKL-40
measurement, and spirometry before (visit 1) and 8 weeks after initiation of treatment (visit 2).
Results: At the follow-up, the median serum YKL-40 level was significantly decreased compared to the levels at visit 1
(75.2 [55.8-86.8] ng/ml versus 54.5 [46.4-58.4] ng/ml, p < 0.001). The serum YKL-40 level was negatively correlated with
%FEV1 (r = -0.37, p < 0.001) and ACT score (r = -0.26, p = 0.007) at visit 1. The change in serum YKL-40 levels between
the visits was significantly correlated with changes in FEV1 (r = -0.28, p = 0.006) and ACT score (r = -0.22, p = 0.037).
Patients with elevated YKL-40 levels had significantly greater corticosteroid use than patients with lower levels.
Conclusions: YKL-40 was reduced in the serum of asthmatic patients after appropriate treatment, and the levels
correlated with improvements in %FEV1 and ACT. High levels of serum YKL-40 may be refractory to current
asthma treatments.
Trial registration: ChiCTR-OCC-13003316
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Asthma is a common chronic disease characterised by
acute inflammation of the airways. Asthma arises from a
complex interaction between genetic factors of the evolv-
ing immune system in the infant and the environment it
encounters [1,2]. Despite recent guidelines focusing on
asthma control, many asthmatic patients remain poorly
controlled under specialist care [3]. Patient outcomes
could be improved by earlier diagnosis and better moni-
toring. Therefore, it is critical to identify new biomarkers
to measure and monitor inflammation within the lungs of* Correspondence: 245737076@qq.com; wubin621011@126.com
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unless otherwise stated.a patient with asthma. The role of chitinase and chitinase-
like proteins in inflammation and tissue remodelling in
human disease has become an important issue.
The chitinase-like protein YKL-40 is also termed chit-
inase 3-like 1 (CHI3L1). It is produced at sites of
inflammation in many cells and is secreted from macro-
phages and smooth muscle cells [4]. YKL-40 binds to
ubiquitously expressed chitin but lacks chitinase activ-
ity. Previous studies have demonstrated that YKL-40
was associated with pathologic conditions characterised
by aberrant cell growth, tissue inflammation and remodel-
ling. Examples of pathologic conditions involving YHL-40
include the following: cancers, diabetes, atherosclerosis,
rheumatoid arthritis, asthma, chronic obstructive pulmon-
ary disease (COPD), liver fibrosis, idiopathic pulmonary fi-
brosis and Crohn’s disease [4-17]. The measurement ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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value in several diseases [5,7,14].
YKL-40 is synthesised in neutrophil precursors and is
stored in the specific granules of neutrophils. YKL-40 se-
cretion is stimulated by the cytokines IL-6, IL-17, and IL-
18 released from neutrophils, vascular smooth muscle,
macrophages, chondrocytes and cancer cells [18]. YKL-40
has been shown to induce activation of the mitogen-
activated protein kinase pathway, nuclear factor-κB tran-
scriptional activity and protein kinase B (Akt) pathway in
cell cultures of human colon cell lines and human chon-
drocytes and synovial cells [9]. YKL-40 also potently stim-
ulates the growth of several types of human fibroblasts
derived from synovium, adult skin, and foetal lung [18].
Moreover, YKL-40 acts a chemoattractant that modulates
vascular endothelial cell morphology by promoting the
formation of branching tubules [19]. A recent study by
Tang et al. demonstrated that YKL-40 may be involved
in the inflammation of asthma by induction of IL-8
from epithelium, which subsequently contributes to
BSMC proliferation and migration [20]. Collectively,
YKL-40 has a role in inflammation, pathological, fibro-
sis and tissue remodelling.
Chupp et al. demonstrated that YKL-40 was highly un-
regulated in alveolar macrophages and the subepithelial
basement membrane of asthmatic patients. Additionally,
the serum YKL-40 level was elevated in asthmatic patients
[10]. Duru et al. showed that serum YKL-40 levels were
higher in non-smoker asthma patients during acute ex-
acerbation than in control individuals [21]. Kuepper et al.
demonstrated that YKL-40 levels were predominantly in-
creased at the site of allergen deposition in response to al-
lergen challenge [22]. A recent study suggested that serum
YKL-40 levels were significantly elevated in patients with
asthma compared to controls. This result indicates that
high levels of serum YKL-40 may be a biological charac-
teristic of asthma exacerbation [23].
Although previous studies have reported elevated
YKL-40 levels in asthmatic patients, the change in serum
YKL-40 levels upon treatment in asthmatic patients and
its correlation with lung function and the asthma control
test (ACT) remain unknown. Therefore, this study was
conducted to determine whether serum YKL-40 levels
are decreased in patients with asthma after the introduc-
tion of appropriate treatment. Furthermore, the relation-
ships between the serum YKL-40 level, lung function
and ACT were also investigated to evaluate the clinical




This study randomly recruited 103 patients (47 women
and 56 men, mean age 33.1 ± 0.9 years) from theOutpatient Clinic, Pulmonary Department, Affiliated
Hospital of Guangdong Medical College. Patients with
no previous diagnosis of asthma presenting with re-
spiratory symptoms were considered eligible for our
study when they were (a) older than 18 years of age, (b)
able to perform spirometry, and (c) literate in Chinese.
Asthma was diagnosed according to the GINA guidelines
based on a history of recurrent episodes of wheezing and
chest tightness with or without cough and impaired spir-
ometry with reversibility in FEV1 of ≥12% and ≥200 ml
after salbutamol administration or hyperresponsiveness to
inhaled methacholine [24]. The exclusion criteria were the
following: current smoking or smoking history of >5 pack
years, oral corticosteroids or respiratory tract infection
within the preceding 4 weeks prior to enrolment, any
chronic cardiopulmonary disease other than asthma (in-
cluding COPD) and pregnancy. We also obtained speci-
mens from the Clinical Research Centre of Guangdong
Medical College Tissue Bank. Although these samples
were not specifically collected for this study, our study
was part of a project that examined the molecular mech-
anism of inflammation in asthma. Bronchial-biopsy speci-
mens were collected from 5 normal subjects who were
non-smokers, 8 patients with mild asthma, 8 patients with
moderate asthma and 7 patients with severe asthma. The
basic characteristics matched those of the present study
participants.
The study protocol was approved by the Ethics of Re-
search Committee of the Medical College of Guangdong
and was registered on the Chinese Clinical Trial Database
(ChiCTR-OCC-13003316, http://www.chictr.org/en/proj/
show.aspx?proj=5084). Written informed consent was ob-
tained from all participants.
Study design
At the baseline visit, all patients underwent a detailed clin-
ical examination and completed a pulmonary function
test, skin prick test (SPT), serum YKL-40 measurement,
and ACT questionnaire. The patients were treated with
appropriate medication according to the GINA guidelines
[24] and were re-evaluated 8 weeks later (visit 2). The
serum YKL-40 level, spirometry and ACT score were mea-
sured at the follow-up visit. Intermittent asthmatic pa-
tients received inhaled salbutamol 100-400 μg per day
(Salbutamol Sulfate for Inhalation, GlaxoSmithKline) as
needed. The mild to moderate and severe asthmatics were
treated with low- to medium-dose budesonide (200-
800 μg per day) delivered via turbuhalers (AstraZeneca
AB) on a regular basis. These patients also received a
beta-2 agonist (either a short-acting beta-2 agonist on an
as-needed basis or a long-acting beta-2 agonist on a
regular basis) and/or a third controller (e.g., leukotriene
antagonists or aminophylline). The patient adherence
to medical treatment was assessed using the Chinese
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Asthma (MARS-A10) items (Additional file 1: Table S1).
MARS-A10 was developed by Horne and collaborators
and is a brief self-measure with good psychometric prop-
erties [25].
Pulmonary function tests
Spirometry was measured with standard spirometric tech-
niques (Jaeger, Germany) at least 6 hours after a patient’s
most recent treatment with albuterol, which is consistent
with the American Thoracic Society (ATS) guidelines [26].
The patients were divided into the following three groups
based on asthma severity according to GINA [24]: (1) mild
asthma (FEV1 ≥ 80%); (2) moderate asthma (FEV1 60-
79%); and (3) severe asthma (FEV1 < 60%).
Skin prick test (SPT) and asthma control test (ACT)
Atopy was tested with the SPT. Twelve common animal
and aeroallergens (ALK-Abello, Horsholm, Denmark)
were tested. The test was considered positive if the wheal
diameter was at least 3 mm. The ACT questionnaires ad-
ministered to the patients of this study had been formally
translated into Chinese. Patients were classified into the
following three groups based on ACT scores [27]: com-
pletely controlled (ACT score = 25), partly controlled
(ACT score range = 20-24), and uncontrolled (ACT score
range = 5-19). Asthma-related quality of life (QoL) was
also measured using the Mini-Asthma QoL Questionnaire
(Mini-AQLQ). The mini AQLQ is a validated 15-item
questionnaire that assesses the quality of life specifically in
relation to asthma [28]. The questionnaire assesses three
domains of asthma interference with daily life (symptoms,
environmental limitations, and emotions). The total score
obtained in the different domains was divided by 15 to
obtain the score for each patient. In this questionnaire,
a higher score indicates a better quality of life [28].
Serum YKL-40 and total serum IgE
The patient serum YKL-40 levels were measured using a
commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Uscn Life Science Inc. Wuhan) ac-
cording to the manufacturer’s instructions. The mini-
mum detection limit of the YKL-40 assay was 12.2 pg/
ml. The total serum IgE levels were determined using a
fluoroenzyme immunoassay from asthmatic patients.
The percentage of peripheral blood eosinophils was de-
tected using a routine blood test.
Immunohistochemistry
Deparaffinised sections (5-μm thick) were immersed in
citrate antigen retrieval solution and preheated to 100°C
for 20 minutes. The endogenous peroxidase was blocked
with immunol staining blocking buffer for 60 min. The
slides were then incubated with a rabbit polyclonal Abagainst human YKL-40 (Uscn Life Science Inc., Wuhan,
China). The immunoreaction was visualised using 3,3-
diaminobenzidine chromogen solution (DAB substrate
kit, Abcam, Cambridge, UK), and the sections were
counterstained with hematoxylin according to the man-
ufacturer’s instructions. Quantitative measurements of
YKL-40-positive cells in the bronchial tissue were per-
formed according to previously described methods [29].
Briefly, YKL-40-positive and -negative cells were counted
in each biopsy specimen separately in the intact epithe-
lium and the submucosa. The bronchial cells positive for
the YKL-40 antibody staining were expressed as a percent-
age of total cells.Statistical analysis
The Kolmogorov-Smirnov (KS) test was performed to
examine the normality of distribution. YKL-40 levels
were not normally distributed, and the values were com-
pared among the study groups using nonparametric tests
including the Mann–Whitney U–test and the Kruskal–
Wallis test. The interrelationships between different pa-
rameters were determined using Spearman’s correlation.
The receiver operating characteristic (ROC) curve analysis
was performed to derive the optimal cut-off value for
YKL-40 as a predictor for an increase in FEV1 and re-
sponse to steroid treatment. All data are presented as the
mean ± SEM or n (%) unless otherwise stated. GraphPad
Prism 5.0 software (GraphPad Software Inc., San Diego,
CA, USA) was used for the analyses and graphs. Statistical
significance was set at a p-value < 0.05.Results
Patient characteristics
This study examined 103 patients with newly diagnosed
asthma (56 men, 47 women, mean age 33.1 ± 0.9). There
were 72 patients with mild asthma (intermittent or
mild), 20 with moderate asthma and 11 with severe
asthma. Sixty-nine patients (67.0%) had at least one
positive SPT result. The most common sensitivities were
to house dust mites and cockroaches. The mean baseline
serum IgE, blood eosinophils in WBCs and body mass
index (BMI) were 631.7 kU/L, 5.4% and 21.6, respect-
ively. The characteristics of participants in our study are
shown in Table 1.
During the follow-up visit, 5 patients were removed
because they were unwilling to complete the treatment
and refused to continue participating. Thus, 98 subjects
completed the study and were included in the data ana-
lyses. There were no significant differences in baseline
characteristics between patients who dropped out and
patients who completed the treatment (Additional file 2:
Table S2).
Table 1 Characteristic of the study participants
Characteristic Visit 1 (n = 103) Visit 2† (n = 98) p-value
Female, n (%) 47 (45.6) 45 (45.9) NS
Age, yrs 33.1 ± 0.9 33.2 ± 0.9 NS
Body mass index 21.6 ± 0.3 21.4 ± 0.2 NS
Nonsmokers, n (%) 81 (78.6) NA
Ex-smokers, n (%) 22 (21.4) NA
Atopic by skin prick, n (%) 69 (67.0) NA
Total IgE, kU/L 631.7 ± 94.1 568.4 ± 86.8 NS
Eosinophil in WBC% 5.4 ± 0.4 4.0 ± 0.3 < 0.001
FEV1/FVC, % 72.1 ± 0.6 74.9 ± 0.8 0.0026
FEV1, % predicted 84.1 ± 1.4 87.8 ± 0.9 0.0270
≥80%, n (%) 72 (69.9) 85 (86.7)
60-79%, n (%) 20 (19.4) 10 (10.2)
< 60%, n (%) 11 (10.7) 3 (3.1)
YKL-40, ng/ml 75.2 (55.8-86.8) 54.5 (46.4-58.4) < 0.001
AQLQ 5.19 ± 0.11 5.35 ± 0.10 NS
ACT score 20.6 ± 0.5 22.1 ± 0.3 0.0101
25, n (%) 26 (25.2) 31 (31.6)
20-24, n (%) 52 (50.5) 60 (61.3)
5-19, n (%) 25 (24.3) 7 (7.1)
Data are presented as mean ± SEM or n (%), except for YKL-40, median (IQR).
Note: FEV1, forced expiratory volume in one second; FVC, forced vital capacity;
AQLQ, Asthma Quality of Life Questionnaire; ACT, asthma control test; NS, not
significant; NA, not assessed.
†Five patients were dropped out.
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At the baseline visit, the mean %FEV1 was 84.1 ± 1.4% and
72 patients (69.9%) had FEV1 ≥ 80%, 20 (19.4%) patients
had FEV1 60-79%, and 11 (10.7%) patients had FEV1 <
60% (Table 1). The mean ACT score was 20.6 ± 0.5, and
26 patients (25.2%) were completely controlled, 52 (50.5%)
patients were partly controlled, and 25 (24.3%) patients
were uncontrolled (Table 1). The patients with completely
controlled asthma had statistically lower serum YKL-40
levels than patients with partly controlled (p < 0.001) and
uncontrolled asthma (p < 0.001). However, there were noFigure 1 Classification of patients based on ACT score at baseline vis
bars indicate mean values.differences in the serum YKL-40 levels between the
partially controlled group and the uncontrolled group
(Figure 1a).
Serum YKL-40 levels in patients with severe asthma
were higher than the levels in the moderate asthma group
(85.60 [56.2-94.3] ng/ml vs. 76.00 [52.9-86.0] ng/ml; p =
0.024) and the mild asthma group (85.60 [56.2-94.3] ng/
ml vs. 63.05 [53.6-75.3] ng/ml; p < 0.001). To confirm this
result, bronchial biopsy specimens specifically stained for
YKL-40 in patients with asthma were further evaluated.
The quantification of lung YKL-40 expression revealed
that YKL-40 expression was higher in mild asthma pa-
tients than in healthy controls (19.15% [14.60-20.75%] vs.
11.70% [9.01-13.85%]; p = 0.006). A subgroup analysis re-
vealed that YKL-40 expression was higher in both severe
and moderate asthma than mild asthma (41.0% [35.8-
44.7%] vs. 19.2% [14.6-20.8%]; p < 0.001 and 29.2% [24.4-
33.3%] vs. 19.2% [14.6-20.8%]; p < 0.001, respectively).
Additionally, severe asthma exhibited significantly higher
YKL-40 levels than mild asthma (41.0% [35.8-44.7%] vs.
29.2% [24.4-33.3%]; p = 0.002) (Figure 2). The serum YKL-
40 level was negatively correlated with %FEV1 (r = -0.37,
p < 0.001) and ACT score (r = -0.26, p = 0.007) at the base-
line visit (Figure 3).
Visit 2
At the follow-up visit, the median serum YKL-40 level was
54.5 [46.4-58.4] ng/ml and the mean %FEV1 was 87.8 ±
0.9%. There were 85 patients (86.7%) that had FEV1 ≥ 80%,
10 (10.2%) patients had FEV1 60-79%, and 3 (3.1%) pa-
tients had FEV1 < 60% (Table 1). The mean ACT score
was 22.1 ± 0.3. Thirty-one patients (31.6%) were com-
pletely controlled, 60 (61.3%) patients were partly con-
trolled, and 7 (7.1%) patients had uncontrolled disease
(Table 1). There were no statistically significant differ-
ences in serum YKL-40 values among patient groups
with different ACT scores (Figure 1b). There were no
correlations between serum YKL-40 and %FEV1 or ACT
score values observed at visit 2 (r = -0.13, p = 0.210 and
r = -0.07, p = 0.511, respectively) (Figure 4).it (a) and visit 2 (b). Note: ***p < 0.0001; NS: not significant. Horizontal
Figure 2 YKL-40 is unregulated in the bronchial tissue of patients with asthma. Specific staining for YKL-40 is brown, whereas nuclei are
stained blue. Representative photomicrographs are present from a) a healthy individual, b) a patient with mild asthma, c) a patient with moderate
asthma, and d) a patient with severe asthma. YKL-40-positive and -negative cells were counted in the epithelium and submucosa (expressed as a
percentage of total cells). The data are presented as medians. e) YKL-40 is increased in both severe and moderate asthma compared with mild
asthma, and there is a significant difference found between the two patient groups.
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As shown in Table 1, there were statistically significant dif-
ferences in serum YKL-40, %FEV1 value and ACT score
between visit 1 and visit 2. We observed statistically sig-
nificant correlations between changes (Δ) in YKL-40 and
ΔFEV1 (r = -0.28, p =0.006) (Figure 5a) and between
ΔYKL-40 and ΔACT (r = -0.22, p = 0.037) (Figure 5b). The
patients who received ICS showed a decrease in serum
YKL-40 levels and an improvement in %FEV1 and in the
ACT score. The mean ΔYKL-40, Δ %FEV1 and ΔACT
values differed significantly between the two medication
groups (Figure 6). The outcomes and the relationship be-
tween treatment with ICS and response were assessed
based on the low-dose administration of ICS (≤400 μg
budesonide per day) and medium- to high-dose adminis-
tration of ICS (>400 μg budesonide per day). PatientsFigure 3 Correlation of serum YKL-40 levels with FEV1 (a) and ACT sc
second; ACT, asthma control test.receiving low-dose ICS have lower YKL-40 levels and
higher %FEV1 and ACT score at baseline compared to pa-
tients receiving medium- to high-dose ICS (Table 2). The
patients with elevated levels of YKL-40 had significantly
greater corticosteroid use than patients with lower levels
(Table 2).
The values of the area under the ROC curve (AUC)
for FEV1 and steroid treatment were 0.76 (95%CI 0.67 to
0.86, p < 0.001) and 0.75 (95%CI 0.63 to 0.85, p = 0.002),
respectively (Figure 7).
The data indicate that serum YKL-40 levels were posi-
tively correlated with blood eosinophils (r = 0.29, p =
0.003) and were weakly positively correlated with total
IgE levels (r = 0.18, p = 0.058). There were no correla-
tions observed between serum YKL-40 levels, FEV1/FVC
(%), age, SPT, BMI and Mini-AQLQ.ore (b) at baseline visit. Note: FEV1, forced expiratory volume in one
Figure 4 Correlations of serum YKL-40 levels with (a) FEV1 and (b) ACT score at visit 2. Note: FEV1, forced expiratory volume in one second;
ACT, asthma control test.
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In this study, we explored the potential role of serum
YKL-40 measurement in the management of asthma.
There were several main findings of our study as follows:
(i) elevated YKL-40 levels in asthma patients were asso-
ciated with disease severity, and serum YKL-40 levels
were deceased in asthmatic patients after administration
of appropriate treatment; (ii) the serum YKL-40 level is
negatively correlated with %FEV1 and ACT score before
asthma treatment; (iii) although these correlations were
no longer observed after treatment, changes in serum
YKL-40, %FEV1 and ACT score continued to correlate
significantly; and (iv) patients who received ICS showed
a significant improvement in serum YKL-40, %FEV1 and
ACT compared with patients without ICS. Patients with
elevated levels of YKL-40 had significantly greater cor-
ticosteroid use than patients with lower levels. These re-
sults suggest that the YKL-40 level is implicated in the
pathophysiology of asthma.
At baseline, the serum YKL-40 levels in the partly con-
trolled group and uncontrolled group were significantly
higher than the levels in the controlled group. However,
there were no differences in the serum YKL-40 levels be-
tween the partly controlled group and the uncontrolled
group. The reason for this finding is unclear, but it may
be explained by the well-known individual variability inFigure 5 Correlation of changes (Δ) in three parameters between the
ΔYKL-40 and ΔFEV1; (b) between ΔYKL-40 and ΔACT. Note: FEV1, forced expirathe perception of symptoms. The patients with uncon-
trolled ACT (≤19)/YLK-40 levels below the median
(≤75.2) (Additional file 3: Figure S1A) may have ad-
equately addressed the atopic inflammation in their air-
ways after treatment. However, these patients continue
to have symptom persistence for other reasons including
co-morbidities (e.g., rhinitis, gastroesophageal reflux dis-
ease), non-eosinophilic asthma and other conditions that
may be similar to asthma. The patients who had ACT
controlled (>19)/YLK-40 levels above the median (>75.2)
(Additional file 3: Figure S1B) were symptomatically
controlled but have evidence of persistent inflammation
and could be at risk for future asthma problems. More-
over, those who were ACT uncontrolled (≤19)/YLK-40
levels above the median (>75.2) (Additional file 3: Figure
S1C) may be part of the symptom controlled/high level
of YKL-40 (>75.2) asthmatics group. This result could
be partly explained by a poor symptom-perception due
to adaptation to their level of disease. These data were
consistent with previous reports that suggested that
asthma evaluation cannot be inferred from single mea-
sures of ACT score [29-32]. GINA also recommends
that questionnaires addressing the level of asthma con-
trol need to be considered in combination with objective
measurements such as lung function and inflammatory
cytokines [24]. To reconcile this issue, we furthertwo visits. Statistically significant correlations were observed (a) between
tory volume in one second; ACT, asthma control test.
Figure 6 Changes in asthma parameters in patient groups
according to medication. Note: FEV1, forced expiratory volume in
one second; ACT, asthma control test. ICS, inhaled corticosteroids;
ICS (+), patients with ICS treatment; ICS (-), patients without ICS
treatment.
Figure 7 Receiver operating characteristic curve showing YKL-40
as a predictor for an increase in FEV1 after treatment (black line)
and as a predictor for response to steroid treatment (red line).
Sens, sensitivity; Spec, specificity; AUC, area under the ROC curve.
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using the asthma severity according to GINA. The data
showed that serum YKL-40 levels for patients in the se-
vere asthma group were higher than the levels in the
moderate and mild asthma groups. To confirm this re-
sult, bronchial biopsy specimens were specifically stained
for YKL-40 in patients with asthma and were then fur-
ther evaluated. The quantification of lung YKL-40 ex-
pression revealed that YKL-40 expression was higher in
mild asthma patients than healthy controls. The sub-
group analysis revealed that severe asthma patients have
significantly higher YKL-40 levels than mild and moder-
ate asthma patients. These findings suggest that the
ACT questionnaire may convey something that inflam-
matory markers and spirometry cannot assess. However,
asthma evaluation control cannot be inferred from single
measures of ACT score and should be considered with
objective measurements (e.g., biomarkers, lung func-
tion). The YKL-40 level is upregulated in human asthma
and is associated with disease severity, which suggests
that high levels of YKL-40 may be a biological character-
istic of asthma severity.
We observed statistically significant correlations be-
tween the serum YKL-40 level and %FEV1 and between
the serum YKL-40 level and ACT score. Specjalski et al.Table 2 Efficacy results in asthma patients at baseline and af
Variable ≤400 μg budesonide per day (n=50
Baseline Visit 2
FEV1, % predicted 90.8 (0.8) 91.2 (0
ACT score 21.3 (0.7) 22.4 (0
YKL-40, ng/ml 59.1 (54.3-86.6) 47.5 (40.3-
Data are presented as mean ± SEM, except for YKL-40, median (IQR).
†p < 0.001 vs. baseline.
§p < 0.001 vs. baseline (≤400 μg budesonide per day).
*p < 0.01 vs. baseline (≤400 μg budesonide per day).showed that in a Polish population, the serum levels of
YKL-40 were significantly higher in patients with uncon-
trolled and partly controlled asthma than in controlled
asthmatic patients and healthy subjects [33]. Chupp
et al. demonstrated that the circulating YKL-40 level was
correlated with lung function, asthma severity, and the
thickness of the subepithelial basement membrane [10].
Additionally, a recent study by Tang et al. showed that
serum YKL-40 levels correlated positively with exacerba-
tion attacks and blood eosinophils. However, the levels
were correlated inversely with lung function [23]. The
exact role of the serum YKL-40 level in asthma is still
unclear and controversial [33-35]. Specjalski et al.
showed that there were no relationships between YKL-
40 and asthma severity or total serum IgE [33]. A recent
study by Sohn et al. suggested that there were noter treatment with budesonide
) >400 μg budesonide per day (n=31)
Baseline Visit 2
.6) 71.6 (2.3)* 82.0 (1.8)†
.5) 19.1 (0.6)§ 22.5 (0.4)†
55.3)† 86.2 (56.4-96.7)* 55.7 (43.8-63.7)†
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tide polymorphisms (SNPs) and asthma in an East
Asian population [34]. The basis for these discrepancies
may be due to ethnic background and differences in
CHI3L1 haplotype structures. The CHI3L1 polymor-
phisms have been associated with features of asthma
and serum YKL-40 levels [36-38]. This suggests that
the CHI3LI gene polymorphism may lead to a reduc-
tion in YKL-40.
At visit 2, no correlations between serum YKL-40 and
%FEV1 or ACT score were observed. One explanation
may be that a majority of patients in our study were
mild asthmatics and showed a response in all three
measurements after administration of appropriate ther-
apy, which minimised the range of their distribution.
However, the changes in serum YKL-40, %FEV1 and
ACT score were significantly correlated. Furthermore,
the serum YKL-40 level declined in asthmatic patients
after appropriate treatment. One possible explanation
for this result could be that ACT scores were signifi-
cantly improved in most patients who presented with a
mild or stable condition after treatment. This result is
consistent with previous studies by Chupp et al. and
Tang et al. that showed that serum YKL-40 levels were
higher in patients with exacerbated asthma than in
stable patients [10]. In addition, our data demonstrated
that patients with asthma receiving regular ICS therapy
had a significant improvement in serum YKL-40, %
FEV1, and ACT. Patients with elevated levels of YKL-40
had significantly greater corticosteroid use than pa-
tients with lower levels. This result suggests that YKL-
40 production may be refractory to current asthma
treatments and may represent an alternative thera-
peutic target for severe asthma [39]. A previous study
demonstrated that serum YKL-40 levels in patients with
active rheumatoid arthritis decreased rapidly during
prednisolone therapy, which suggests that steroids may
have a direct effect on expression of YKL-40 [40]. How-
ever, it should be noted that patients were treated with
ICS, but differences in dosing and compliance existed
and serum YKL-40 levels may be influenced by the
CHI3LI gene polymorphism or other medications such
as bronchodilators.
There are some limitations to this study that need to
be considered. Asthmatic patients with newly diagnosis
asthma were enrolled in our study, and most patients
(69.9%, 72/103) had mild asthma. Our results may not
fully reflect the general population of asthmatic pa-
tients, especially patients with severe therapy-resistant
asthma. Additionally, we did not consider the Asthma
Control Questionnaire (ACQ) because the ACQ has
not been validated in the Chinese population and the
ACT is easier to score and provides the same screening
accuracy [29,41,42].Conclusions
In summary, our current findings demonstrate that ele-
vated YKL-40 levels in asthma patients correlate with
disease severity. Patients with elevated levels of YKL-40
had significantly greater corticosteroid use than pa-
tients with lower levels, which suggests that high levels
of serum YKL-40 may be refractory to current asthma
treatments. Future prospective studies are required to
determine the role of YKL-40 in patients with severe
therapy-resistant asthma and will assess whether YKL-40
gene expression is directly controlled by corticosteroids.
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